EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)

Saakshi Khattri, Álvaro González-Cantero, Burhan Engin, Sunil Dogra, Caroline A Murphy, Christopher Schuster, Naoto Tsujimoto, Georgia Martimianaki, Anastasia Lampropoulou, Aya Alsharafi, Bruce Konicek, Felix Lauffer

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03034-1 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Advances in Therapy, 2025. Verfasst von Saakshi Khattri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, USA. Hauptthemen laut MEDLINE: Psoriasis, Biological Products, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Studies directly comparing the effectiveness of different biologics over long observation periods are lacking. As many treatment guidelines are formulated based on drug class, there is a particular need to compare drug classes rather than specific biologic agents. METHODS: This post hoc analysis compares the effectiveness and durability of biologics that target the interleukin (IL)-17 A ligands or the IL-17 receptor A (IL-17RA) relative to other approved drug classes in patients with moderate-to-severe plaque psoriasis, through 12 months in a real-world setting. RESULTS: In the Psoriasis Study of Health Outcomes (PSoHO) (N = 1981), patients treated with anti-IL-17A/RA resulted in a higher proportion of patients who achieved the primary outcome [proportion of patients who had at least a 90% improvement in Psoriasis Area and Severity Index score (PASI90) and/or a score of 0 or 1 in static Physician Global Assessment (sPGA)] compared to anti-IL-23-, anti-IL-12/23-, and tumor necrosis factor (TNF)-α-treated patients at week 12, month 6, and month 12, except versus anti-IL-23 at month 12. Similar trends were observed for a 100% improvement in PASI score (PASI100), PASI90, and Dermatology Life Quality Index score of 0 or 1 [DLQI (0,1)]. At month 12, the unadjusted response rates across the drug classes were 53.5-69.1% for the primary outcome, 27.6-40.8% for PASI100, 41.7-55.9% for PASI90, and 31.8-33.0% for DLQI (0,1). Regarding the durability of effectiveness, anti-IL-17A/RA patients had the highest response rate, and for the adjusted analysis, using Frequentist Model Averaging (FMA), patients had 1.4-2.6 times higher odds of achieving the primary durability outcome compared to patients treated with any other drug class. CONCLUSION: Overall, anti-IL-17A/RA had the highest effectiveness of achieving early response to treatment and maintaining that response through 12 months compared to other drug classes. TRIAL REGISTRATION: The study was registered at the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP24207).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsDermatologic AgentsHumansMaleFemaleMiddle AgedInterleukin-17Severity of Illness IndexAdultTreatment OutcomeReceptors, Interleukin-17Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalInterleukin-23Comparative Effectiveness Research

Stichwörter der Autor:innen

Biologic therapiesDLQIIL-17APASI100PASI90PSoHOPsoriasis

Substanzen

Interleukin-17Biological ProductsReceptors, Interleukin-17Dermatologic AgentsAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalInterleukin-23

Autor:innen und Institutionen

  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, USA.
  • Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS, Colmenar Viejo Km 9.100, 28034, Madrid, Spain.
  • Faculty of Medicine, Universidad Francisco de Vitoria, 28223, Madrid, Spain.
  • Department of Dermatology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Eli Lilly and Company, Indianapolis, IN, USA. caroline.murphy@lilly.com.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Khattri, S., González-Cantero, Á., Engin, B., Dogra, S., Murphy, C. A., Schuster, C., Tsujimoto, N., Martimianaki, G., Lampropoulou, A., Alsharafi, A., Konicek, B., & Lauffer, F. (2025). Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO). Advances in Therapy. https://doi.org/10.1007/s12325-024-03034-1

Vancouver

Khattri S, González-Cantero Á, Engin B, Dogra S, Murphy CA, Schuster C, et al. Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO). Advances in Therapy. 2025. doi:10.1007/s12325-024-03034-1

BibTeX
@article{Khattri2025,
  author = {Khattri, Saakshi and González-Cantero, Álvaro and Engin, Burhan and Dogra, Sunil and Murphy, Caroline A and Schuster, Christopher and Tsujimoto, Naoto and Martimianaki, Georgia and Lampropoulou, Anastasia and Alsharafi, Aya and Konicek, Bruce and Lauffer, Felix},
  title = {Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03034-1}
}
Kostenlos starten →